Telix Pharmaceuticals Limited

Fundamentals6.0
Price Action6.0
News Sentiment7.0
AI Rating
6.0

Key Drivers

  • High gross margin
  • Negative operating cash
  • Elevated leverage

AI
AI Summary

6.0

Telix has evolved into a revenue‑driven commercial imaging platform—so the investment thesis now hinges on execution (Illuccix/Gozellix adoption, reimbursement wins, and manufacturing scale) rather than pure clinical binary upside; investors should therefore prioritize quarterly cash‑flow inflection, FY26 revenue cadence vs. guide, and demonstrable net‑debt reduction as the key validation signals. The biggest immediate downside is balance‑sheet and legal fragility: continued negative operating cash flow, manufacturing or reimbursement setbacks, or an adverse securities outcome could force dilutive financing and materially compress the multiple.

CommercialMomentum
LegalRisk
CashFlow‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • High gross margin
  • Negative operating cash
  • Elevated leverage

TLX shows resilient product economics with high gross margins and modest operating profit but is a cash‑burning, highly leveraged company with a slight net loss and stretched valuation.

cashrisk
solidcore

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Short-term uptrend
  • Price stretched
  • Support cluster

TLX is in a short-term uptrend, trading at $8.75 (~15% above its last-month SMA of ~$7.58) and near a recent high, but the move is extended and vulnerable to a pullback with support near $7.60, $6.87 and $6.56.

Bullish
Overstretched
Support Level: $7.60, $6.87, $6.56
Resistance Level: $8.75; $8.10–$8.36

Price ~15% above last-month

Sentiment & News

7.0

Key News Insights:

  • Commercial momentum
  • Phase 3 safety
  • Manufacturing expansion

Telix posted strong FY2025 results ($804M, +56%) led by Illuccix/Gozellix ($622M), signaled a path to a ~$1B run‑rate, advanced TLX591‑Tx Phase 3 safety objectives, resubmitted the TLX101‑Px NDA, and is scaling U.S. manufacturing while launching AI‑PET research.

CommercialMomentum

The combination of robust commercial uptake, late‑stage therapeutic de‑risking, and manufacturing scale‑up materially improves Telix's near‑term revenue visibility and commercialization risk profile